HIGHLIGHTS
SUMMARY
The results of the pilot RCT1 also provide the data for estimating the sample sizes for RCTs primarily aimed to compare the stool bacterial community structures between the probiotic and placebo groups. Future RCTs, if of adequate sample size, could include even very preterm ( and amp;lt;32 weeks) and extremely preterm ( and amp;lt;28 weeks) infants with CGISC. Probiotic supplementation is safe and beneficial even in extremely preterm infants without surgical conditions and reduces the risk of NEC, feed intolerance, and lateonset sepsis.11-15 RANDOMISATION Since the pilot RCT1 had a . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.